<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32793228</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.</ArticleTitle>
        <Pagination>
          <StartPage>1590</StartPage>
          <MedlinePgn>1590</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1590</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2020.01590</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors are becoming standard treatments in several cancer types, profoundly changing the prognosis of a fraction of patients. Currently, many efforts are being made to predict responders and to understand how to overcome resistance in non-responders. Given the crucial role of myeloid cells as modulators of T effector cell function in tumors, it is essential to understand their impact on the clinical outcome of immune checkpoint blockade and on the mechanisms of immune evasion. In this review we focus on the existing clinical evidence of the relation between the presence of myeloid cell subsets and the response to anti-PD(L)1 and anti-CTLA-4 treatment. We highlight how circulating and tumor-infiltrating myeloid populations can be used as predictive biomarkers for immune checkpoint inhibitors in different human cancers, both at baseline and on treatment. Moreover, we propose to follow the dynamics of myeloid cells during immunotherapy as pharmacodynamic biomarkers. Finally, we provide an overview of the current strategies tested in the clinic that use myeloid cell targeting together with immune checkpoint blockade with the aim of uncovering the most promising approaches for effective combinations.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Peranzoni, Ingangi, Masetto, Pinton and Marigo.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Peranzoni</LastName>
            <ForeName>Elisa</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Therapeutic Innovation in Oncology, Institut de Recherche International Servier, Suresnes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ingangi</LastName>
            <ForeName>Vincenzo</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Masetto</LastName>
            <ForeName>Elena</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinton</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marigo</LastName>
            <ForeName>Ilaria</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082102">Immune Checkpoint Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068456" MajorTopicYN="N">Clinical Studies as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082102" MajorTopicYN="N">Immune Checkpoint Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072737" MajorTopicYN="N">Myeloid-Derived Suppressor Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">MDSC (myeloid-derived suppressor cell)</Keyword>
        <Keyword MajorTopicYN="Y">TAM (tumor-associated macrophage)</Keyword>
        <Keyword MajorTopicYN="Y">circulating biomarkers</Keyword>
        <Keyword MajorTopicYN="Y">immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="Y">myeloid cells</Keyword>
        <Keyword MajorTopicYN="Y">predictive biomarkers</Keyword>
        <Keyword MajorTopicYN="Y">resistance to immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">tumor biomarkers</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32793228</ArticleId>
        <ArticleId IdType="pmc">PMC7393010</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2020.01590</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. (2012) 12:252–64. 10.1038/nrc3239</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3239</ArticleId>
            <ArticleId IdType="pmc">PMC4856023</ArticleId>
            <ArticleId IdType="pubmed">22437870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canè S, Ugel S, Trovato R, Marigo I, De Sanctis F, Sartoris S, et al. . The Endless saga of monocyte diversity. Front Immunol. (2019) 10:1786. 10.3389/fimmu.2019.01786</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01786</ArticleId>
            <ArticleId IdType="pmc">PMC6691342</ArticleId>
            <ArticleId IdType="pubmed">31447834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peranzoni E, Donnadieu E. Improving efficacy of cancer immunotherapy through targeting of macrophages. Hum Vacc Immunother. (2019) 15:189–92. 10.1080/21645515.2018.1515447</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2018.1515447</ArticleId>
            <ArticleId IdType="pmc">PMC6363160</ArticleId>
            <ArticleId IdType="pubmed">30192699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bercovici N, Guérin MV, Trautmann A, Donnadieu E. The remarkable plasticity of macrophages: a chance to fight cancer. Front Immunol. (2019) 10:1563. 10.3389/fimmu.2019.01563</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01563</ArticleId>
            <ArticleId IdType="pmc">PMC6640155</ArticleId>
            <ArticleId IdType="pubmed">31354719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. (2018) 17:887–904. 10.1038/nrd.2018.169</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd.2018.169</ArticleId>
            <ArticleId IdType="pubmed">30361552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. (2020) 17:1–12. 10.1038/s41423-019-0306-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41423-019-0306-1</ArticleId>
            <ArticleId IdType="pmc">PMC6952382</ArticleId>
            <ArticleId IdType="pubmed">31611651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, et al. . Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. (2018) 9:1310. 10.3389/fimmu.2018.01310</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01310</ArticleId>
            <ArticleId IdType="pmc">PMC6004385</ArticleId>
            <ArticleId IdType="pubmed">29942309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park S-M, Youn J-I. Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer. Arch Pharm Res. (2019) 42:560–6. 10.1007/s12272-019-01165-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12272-019-01165-6</ArticleId>
            <ArticleId IdType="pubmed">31147902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P. Immune checkpoint therapy and the search for predictive biomarkers. Cancer J. (2016) 22:68–72. 10.1097/PPO.0000000000000185</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PPO.0000000000000185</ArticleId>
            <ArticleId IdType="pmc">PMC4847150</ArticleId>
            <ArticleId IdType="pubmed">27111900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS. Biomarkers for checkpoint inhibition. Am Soc Clin Oncol Educ Book. (2018) 37:205–9. 10.1200/EDBK_175463</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/EDBK_175463</ArticleId>
            <ArticleId IdType="pubmed">28561695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. (2019) 19:133–50. 10.1038/s41568-019-0116-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-019-0116-x</ArticleId>
            <ArticleId IdType="pmc">PMC6705396</ArticleId>
            <ArticleId IdType="pubmed">30755690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ballman KV.
Biomarker: predictive or prognostic?
J Clin Oncol. (2015) 33:3968–71. 10.1200/JCO.2015.63.3651</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.63.3651</ArticleId>
            <ArticleId IdType="pubmed">26392104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. (2016) 17:e542–51. 10.1016/S1470-2045(16)30406-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(16)30406-5</ArticleId>
            <ArticleId IdType="pmc">PMC5702534</ArticleId>
            <ArticleId IdType="pubmed">27924752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hofman P, Heeke S, Alix-Panabières C, Pantel K. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Ann Oncol. (2019) 30:1448–59. 10.1093/annonc/mdz196</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz196</ArticleId>
            <ArticleId IdType="pubmed">31228184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M, et al. . Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer. (2016) 114:256–61. 10.1038/bjc.2015.467</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2015.467</ArticleId>
            <ArticleId IdType="pmc">PMC4742588</ArticleId>
            <ArticleId IdType="pubmed">26794281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Tanese K, et al. . Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget. (2016) 7:77404–15. 10.18632/oncotarget.12677</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.12677</ArticleId>
            <ArticleId IdType="pmc">PMC5363594</ArticleId>
            <ArticleId IdType="pubmed">27764805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. (2017) 14:531–48. 10.1038/nrclinonc.2017.14</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.14</ArticleId>
            <ArticleId IdType="pubmed">28252003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J, et al. . Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol. (2019) 5:696–702. 10.1001/jamaoncol.2018.7098</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.7098</ArticleId>
            <ArticleId IdType="pmc">PMC6512308</ArticleId>
            <ArticleId IdType="pubmed">30816954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, et al. . Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci USA. (2017) 114:4993–8. 10.1073/pnas.1705327114</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1705327114</ArticleId>
            <ArticleId IdType="pmc">PMC5441721</ArticleId>
            <ArticleId IdType="pubmed">28446615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder A, Nathanson T, Funt SA, Ahuja A, Novik JB, Hellmann MD, et al. . Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis. PLoS Med. (2017) 14:e1002309. 10.1371/journal.pmed.1002309</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1002309</ArticleId>
            <ArticleId IdType="pmc">PMC5446110</ArticleId>
            <ArticleId IdType="pubmed">28552987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. . Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. (2014) 6:238ra70. 10.1126/scitranslmed.3008211</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3008211</ArticleId>
            <ArticleId IdType="pmc">PMC4558099</ArticleId>
            <ArticleId IdType="pubmed">24871131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. (2017) 5:3–8. 10.1158/2326-6066.CIR-16-0297</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0297</ArticleId>
            <ArticleId IdType="pmc">PMC5426480</ArticleId>
            <ArticleId IdType="pubmed">28052991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, et al. . Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commu. (2016) 7:12150. 10.1038/ncomms12150</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms12150</ArticleId>
            <ArticleId IdType="pmc">PMC4935811</ArticleId>
            <ArticleId IdType="pubmed">27381735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapellos TS, Bonaguro L, Gemünd I, Reusch N, Saglam A, Hinkley ER, et al. . Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. (2019) 10:2035. 10.3389/fimmu.2019.02035</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.02035</ArticleId>
            <ArticleId IdType="pmc">PMC6728754</ArticleId>
            <ArticleId IdType="pubmed">31543877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green R, Wachsmann-Hogiu S. Development, history, and future of automated cell counters. Clin Lab Med. (2015) 35:1–10. 10.1016/j.cll.2014.11.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cll.2014.11.003</ArticleId>
            <ArticleId IdType="pubmed">25676368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, et al. . The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. J Exp Med. (2017) 214:1913–23. 10.1084/jem.20170355</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20170355</ArticleId>
            <ArticleId IdType="pmc">PMC5502436</ArticleId>
            <ArticleId IdType="pubmed">28606987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khunger M, Patil PD, Khunger A, Li M, Hu B, Rakshit S, et al. . Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS ONE. (2018) 13:e0197743. 10.1371/journal.pone.0197743</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0197743</ArticleId>
            <ArticleId IdType="pmc">PMC6201866</ArticleId>
            <ArticleId IdType="pubmed">30359383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen H, Yang ES-H, Conry M, Fiveash J, Contreras C, Bonner JA, et al. . Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes Dis. (2019) 6:232–46. 10.1016/j.gendis.2019.06.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gendis.2019.06.006</ArticleId>
            <ArticleId IdType="pmc">PMC6997608</ArticleId>
            <ArticleId IdType="pubmed">32042863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. (2018) 24:1550–8. 10.1038/s41591-018-0136-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0136-1</ArticleId>
            <ArticleId IdType="pmc">PMC6487502</ArticleId>
            <ArticleId IdType="pubmed">30127393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. . B cells and tertiary lymphoid structures promote immunotherapy response. Nature. (2020) 577:549–55. 10.1038/s41586-019-1922-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1922-8</ArticleId>
            <ArticleId IdType="pubmed">31942075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elliott LA, Doherty GA, Sheahan K, Ryan EJ. Human tumor-infiltrating myeloid cells: phenotypic and functional diversity. Front Immunol. (2017) 8:86. 10.3389/fimmu.2017.00086</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.00086</ArticleId>
            <ArticleId IdType="pmc">PMC5292650</ArticleId>
            <ArticleId IdType="pubmed">28220123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fridman WH, Zitvogel L, Sautès–Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. (2017) 14:717–34. 10.1038/nrclinonc.2017.101</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.101</ArticleId>
            <ArticleId IdType="pubmed">28741618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. . The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. (2015) 21:938–45. 10.1038/nm.3909</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3909</ArticleId>
            <ArticleId IdType="pmc">PMC4852857</ArticleId>
            <ArticleId IdType="pubmed">26193342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng Q, Chang W, Mao Y, He G, Zheng P, Tang W, et al. . Tumor-associated macrophages as prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage ii colon cancer. Clin Cancer Res. (2019) 25:3896–907. 10.1158/1078-0432.CCR-18-2076</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-2076</ArticleId>
            <ArticleId IdType="pubmed">30988081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, et al. . Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. (2019) 35:588–602.e10. 10.1016/j.ccell.2019.02.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2019.02.009</ArticleId>
            <ArticleId IdType="pmc">PMC6472943</ArticleId>
            <ArticleId IdType="pubmed">30930117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. (2012) 12:253–68. 10.1038/nri3175</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3175</ArticleId>
            <ArticleId IdType="pmc">PMC3587148</ArticleId>
            <ArticleId IdType="pubmed">22437938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res. (2013) 19:4917–24. 10.1158/1078-0432.CCR-12-1972</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1972</ArticleId>
            <ArticleId IdType="pmc">PMC4005613</ArticleId>
            <ArticleId IdType="pubmed">23868869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. (2016) 375:1767–78. 10.1056/NEJMra1514296</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1514296</ArticleId>
            <ArticleId IdType="pmc">PMC5575761</ArticleId>
            <ArticleId IdType="pubmed">27806234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. (2015) 27:450–61. 10.1016/j.ccell.2015.03.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2015.03.001</ArticleId>
            <ArticleId IdType="pmc">PMC4400238</ArticleId>
            <ArticleId IdType="pubmed">25858804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. . Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. (2012) 366:2443–54. 10.1056/NEJMoa1200690</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200690</ArticleId>
            <ArticleId IdType="pmc">PMC3544539</ArticleId>
            <ArticleId IdType="pubmed">22658127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. (2014) 515:558–62. 10.1038/nature13904</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13904</ArticleId>
            <ArticleId IdType="pubmed">25428503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. . Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. (2015) 373:1627–39. 10.1056/NEJMoa1507643</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1507643</ArticleId>
            <ArticleId IdType="pmc">PMC5705936</ArticleId>
            <ArticleId IdType="pubmed">26412456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. . Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. (2015) 373:1803–13. 10.1056/NEJMoa1510665</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1510665</ArticleId>
            <ArticleId IdType="pmc">PMC5719487</ArticleId>
            <ArticleId IdType="pubmed">26406148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. . Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. (2015) 16:257–65. 10.1016/S1470-2045(15)70054-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(15)70054-9</ArticleId>
            <ArticleId IdType="pmc">PMC5726228</ArticleId>
            <ArticleId IdType="pubmed">25704439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. 
PD-1 blockade with nivolumab in relapsed or refractory hodgkin's lymphoma. N Engl J Med. (2015) 372:311–9. 10.1056/NEJMoa1411087</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1411087</ArticleId>
            <ArticleId IdType="pmc">PMC4348009</ArticleId>
            <ArticleId IdType="pubmed">25482239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. (2019) 7:278. 10.1186/s40425-019-0768-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0768-9</ArticleId>
            <ArticleId IdType="pmc">PMC6815032</ArticleId>
            <ArticleId IdType="pubmed">31655605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. (2014) 515:568–71. 10.1038/nature13954</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13954</ArticleId>
            <ArticleId IdType="pmc">PMC4246418</ArticleId>
            <ArticleId IdType="pubmed">25428505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, et al. . Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin Cancer Res. (2017) 23:5024–33. 10.1158/1078-0432.CCR-16-0698</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-0698</ArticleId>
            <ArticleId IdType="pubmed">28512174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber J, Gibney G, Kudchadkar R, Yu B, Cheng P, Martinez AJ, et al. . Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res. (2016) 4:345–53. 10.1158/2326-6066.CIR-15-0193</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0193</ArticleId>
            <ArticleId IdType="pmc">PMC4818672</ArticleId>
            <ArticleId IdType="pubmed">26873574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Limagne E, Richard C, Thibaudin M, Fumet J-D, Truntzer C, Lagrange A, et al. . Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. OncoImmunology. (2019) 8:e1564505. 10.1080/2162402X.2018.1564505</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1564505</ArticleId>
            <ArticleId IdType="pmc">PMC6422400</ArticleId>
            <ArticleId IdType="pubmed">30906658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, et al. . Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. (2015) 21:712–20. 10.1158/1078-0432.CCR-14-2468</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2468</ArticleId>
            <ArticleId IdType="pmc">PMC4620684</ArticleId>
            <ArticleId IdType="pubmed">25524312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG, Finke JH, et al. . Immunological correlates of response to immune checkpoint inhibitors in metastatic urothelial carcinoma. Targ Oncol. (2018) 13:599–609. 10.1007/s11523-018-0595-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11523-018-0595-9</ArticleId>
            <ArticleId IdType="pubmed">30267200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. . Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. (2019) 25:477–86. 10.1038/s41591-018-0337-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0337-7</ArticleId>
            <ArticleId IdType="pmc">PMC6408961</ArticleId>
            <ArticleId IdType="pubmed">30742122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chasseuil E, Saint-Jean M, Chasseuil H, Peuvrel L, Quéreux G, Nguyen J-M, et al. . Blood predictive biomarkers for nivolumab in advanced melanoma. Acta Derm Venereol. (2018) 98:406–10. 10.2340/00015555-2872</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2340/00015555-2872</ArticleId>
            <ArticleId IdType="pubmed">29327065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekine K, Kanda S, Goto Y, Horinouchi H, Fujiwara Y, Yamamoto N, et al. . Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer. (2018) 124:179–88. 10.1016/j.lungcan.2018.08.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2018.08.012</ArticleId>
            <ArticleId IdType="pubmed">30268458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitano S, Postow MA, Ziegler CGK, Kuk D, Panageas KS, Cortez C, et al. . Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res. (2014) 2:812–21. 10.1158/2326-6066.CIR-14-0013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0013</ArticleId>
            <ArticleId IdType="pmc">PMC4125466</ArticleId>
            <ArticleId IdType="pubmed">24844912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. (2010) 70:4335–45. 10.1158/0008-5472.CAN-09-3767</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-3767</ArticleId>
            <ArticleId IdType="pubmed">20484028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res. (2012) 18:5212–23. 10.1158/1078-0432.CCR-12-1108</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1108</ArticleId>
            <ArticleId IdType="pmc">PMC6374773</ArticleId>
            <ArticleId IdType="pubmed">22837179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, et al. . Author correction: high-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. (2018) 24:1773–5. 10.1038/s41591-018-0094-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0094-7</ArticleId>
            <ArticleId IdType="pubmed">29967347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parikh K, Kumar A, Ahmed J, Anwar A, Puccio C, Chun H, et al. . Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer. Cancer Immunol Immunother. (2018) 67:1365–70. 10.1007/s00262-018-2192-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-018-2192-2</ArticleId>
            <ArticleId IdType="pubmed">29968154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HR, Park S-M, Seo S-U, Jung I, Yoon HI, Gabrilovich DI, et al. . The ratio of peripheral regulatory T cells to Lox-1+ polymorphonuclear myeloid-derived suppressor cells predicts the early response to anti–PD-1 therapy in patients with non–small cell lung cancer. Am J Respir Crit Care Med. (2018) 199:243–6. 10.1164/rccm.201808-1502LE</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201808-1502LE</ArticleId>
            <ArticleId IdType="pmc">PMC6835091</ArticleId>
            <ArticleId IdType="pubmed">30339766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Passaro A, Mancuso P, Gandini S, Spitaleri G, Labanca V, Guerini-Rocco E, et al. 
Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy. Clin Transl Oncol. (2019) 22:603–11. 10.1007/s12094-019-02166-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12094-019-02166-z</ArticleId>
            <ArticleId IdType="pubmed">31254252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, et al. . Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. (2018) 6:74. 10.1186/s40425-018-0383-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0383-1</ArticleId>
            <ArticleId IdType="pmc">PMC6048712</ArticleId>
            <ArticleId IdType="pubmed">30012216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bilen MA, Dutcher GMA, Liu Y, Ravindranathan D, Kissick HT, Carthon BC, et al. . Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab. Clin Genitourin Cancer. (2018) 16:e563–75. 10.1016/j.clgc.2017.12.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clgc.2017.12.015</ArticleId>
            <ArticleId IdType="pmc">PMC5970007</ArticleId>
            <ArticleId IdType="pubmed">29402706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeyakumar G, Kim S, Bumma N, Landry C, Silski C, Suisham S, et al. . Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. J Immunother Cancer. (2017) 5:82. 10.1186/s40425-017-0287-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0287-5</ArticleId>
            <ArticleId IdType="pmc">PMC5646127</ArticleId>
            <ArticleId IdType="pubmed">29041991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, et al. . Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. (2017) 106:1–7. 10.1016/j.lungcan.2017.01.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2017.01.013</ArticleId>
            <ArticleId IdType="pubmed">28285682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. . Neutrophil-to-Lymphocyte ratio (NLR) and platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. (2017) 111:176–81. 10.1016/j.lungcan.2017.07.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2017.07.024</ArticleId>
            <ArticleId IdType="pubmed">28838390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Putzu C, Cortinovis DL, Colonese F, Canova S, Carru C, Zinellu A, et al. . Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with nivolumab. Cancer Immunol Immunother. (2018) 67:1349–53. 10.1007/s00262-018-2182-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-018-2182-4</ArticleId>
            <ArticleId IdType="pubmed">29947960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, et al. . Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol. (2018) 23:634–40. 10.1007/s10147-018-1250-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10147-018-1250-2</ArticleId>
            <ArticleId IdType="pmc">PMC6097082</ArticleId>
            <ArticleId IdType="pubmed">29442281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. . The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS ONE. (2018) 13:e0193018. 10.1371/journal.pone.0193018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0193018</ArticleId>
            <ArticleId IdType="pmc">PMC5814002</ArticleId>
            <ArticleId IdType="pubmed">29447258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, et al. . Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother. (2018) 67:459–470. 10.1007/s00262-017-2092-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-2092-x</ArticleId>
            <ArticleId IdType="pubmed">29204702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nassar AH, Mouw KW, Jegede O, Shinagare AB, Kim J, Liu C-J, et al. . A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Br J Cancer. (2020) 122:555–63. 10.1038/s41416-019-0686-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-019-0686-0</ArticleId>
            <ArticleId IdType="pmc">PMC7028947</ArticleId>
            <ArticleId IdType="pubmed">31857723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan M, Alavi M, Herrinton LJ. Association of inflammatory markers with disease progression in patients with metastatic melanoma treated with immune checkpoint inhibitors. Perm J. (2018) 22:17–149. 10.7812/TPP/17-149</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7812/TPP/17-149</ArticleId>
            <ArticleId IdType="pmc">PMC5882187</ArticleId>
            <ArticleId IdType="pubmed">29616914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanizaki J, Haratani K, Hayashi H, Chiba Y, Nakamura Y, Yonesaka K, et al. . Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol. (2018) 13:97–105. 10.1016/j.jtho.2017.10.030</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2017.10.030</ArticleId>
            <ArticleId IdType="pubmed">29170120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okuhira H, Yamamoto Y, Inaba Y, Kunimoto K, Mikita N, Ikeda T, et al. . Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab. Biosci Trends. (2018) 12:412–8. 10.5582/bst.2018.01158</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5582/bst.2018.01158</ArticleId>
            <ArticleId IdType="pubmed">30158364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang W, Ferrara N. The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol Res. (2016) 4:83–91. 10.1158/2326-6066.CIR-15-0313</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0313</ArticleId>
            <ArticleId IdType="pubmed">26839309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, et al. . Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. (2016) 22:5487–96. 10.1158/1078-0432.CCR-16-0127</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-0127</ArticleId>
            <ArticleId IdType="pmc">PMC5572569</ArticleId>
            <ArticleId IdType="pubmed">27185375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, et al. . Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer. (2017) 82:56–65. 10.1016/j.ejca.2017.05.038</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2017.05.038</ArticleId>
            <ArticleId IdType="pubmed">28648699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. (2015) 16:609–17. 10.1038/ni.3159</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3159</ArticleId>
            <ArticleId IdType="pubmed">25915731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. . Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. (2016) 165:35–44. 10.1016/j.cell.2016.02.065</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.02.065</ArticleId>
            <ArticleId IdType="pmc">PMC4808437</ArticleId>
            <ArticleId IdType="pubmed">26997480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, et al. . T cell–induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med. (2018) 10:eaan3311. 10.1126/scitranslmed.aan3311</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aan3311</ArticleId>
            <ArticleId IdType="pmc">PMC5957531</ArticleId>
            <ArticleId IdType="pubmed">29643229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, et al. . Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respir Med. (2018) 6:771–81. 10.1016/S2213-2600(18)30284-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(18)30284-4</ArticleId>
            <ArticleId IdType="pubmed">30100403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, et al. . Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. (2020) 26:39–46. 10.1038/s41591-019-0694-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0694-x</ArticleId>
            <ArticleId IdType="pmc">PMC7182038</ArticleId>
            <ArticleId IdType="pubmed">31873309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, et al. . Antibody–Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non–small cell lung cancer subsequent to PD-1/PD-L1 blockade. Clin Cancer Res. (2019) 25:989–99. 10.1158/1078-0432.CCR-18-1390</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1390</ArticleId>
            <ArticleId IdType="pubmed">30206165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen P-L, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. . Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Dis. (2016) 6:827–37. 10.1158/2159-8290.CD-15-1545</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-15-1545</ArticleId>
            <ArticleId IdType="pmc">PMC5082984</ArticleId>
            <ArticleId IdType="pubmed">27301722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, et al. . Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proc Natl Acad Soc USA. (2018) 115:E4041–50. 10.1073/pnas.1720948115</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1720948115</ArticleId>
            <ArticleId IdType="pmc">PMC5924916</ArticleId>
            <ArticleId IdType="pubmed">29632196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. 
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression. J Clin Invest. (2018) 128:12
10.1172/JCI120803</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI120803</ArticleId>
            <ArticleId IdType="pmc">PMC5873851</ArticleId>
            <ArticleId IdType="pubmed">29608143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keung EZ, Burgess M, Salazar R, Parra Cuentas E, Rodrigues-Canales J, Bolejack V, et al. . Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin Cancer Res. (2020) 26:1258–66. 10.1158/1078-0432.CCR-19-1824</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-1824</ArticleId>
            <ArticleId IdType="pmc">PMC7731262</ArticleId>
            <ArticleId IdType="pubmed">31900276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger SN, Herbst RS, et al. . Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clin Cancer Res. (2019) 26:970–7. 10.1158/1078-0432.CCR-19-1040</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-1040</ArticleId>
            <ArticleId IdType="pmc">PMC7024671</ArticleId>
            <ArticleId IdType="pubmed">31615933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. . Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. (2018) 175:998–1013.e20. 10.1016/j.cell.2018.10.038</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.10.038</ArticleId>
            <ArticleId IdType="pmc">PMC6641984</ArticleId>
            <ArticleId IdType="pubmed">30388456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. . Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. (2020) 26:487–504. 10.1158/1078-0432.CCR-19-1868</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-1868</ArticleId>
            <ArticleId IdType="pubmed">31636098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. . Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. (2017) 171:934–49.e16. 10.1016/j.cell.2017.09.028</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.028</ArticleId>
            <ArticleId IdType="pmc">PMC5685550</ArticleId>
            <ArticleId IdType="pubmed">29033130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang S, Kwon A-Y, Jeong J-Y, Kim S, Kang H, Park J, et al. . Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep. (2020) 10:643. 10.1038/s41598-019-57218-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-57218-9</ArticleId>
            <ArticleId IdType="pmc">PMC6971301</ArticleId>
            <ArticleId IdType="pubmed">31959763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, et al. . A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. (2019) 25:454–61. 10.1038/s41591-019-0357-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0357-y</ArticleId>
            <ArticleId IdType="pmc">PMC6699626</ArticleId>
            <ArticleId IdType="pubmed">30804515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo G, Yu M, Xiao W, Celis E, Cui Y. Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity. Cancer Res. (2017) 77:2292–305. 10.1158/0008-5472.CAN-16-2832</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-2832</ArticleId>
            <ArticleId IdType="pmc">PMC5465961</ArticleId>
            <ArticleId IdType="pubmed">28280037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. . Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. (2018) 378:1976–86. 10.1056/NEJMc1808251</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1808251</ArticleId>
            <ArticleId IdType="pmc">PMC6223617</ArticleId>
            <ArticleId IdType="pubmed">29658848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. . Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. (2018) 29:1853–60. 10.1093/annonc/mdy218</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy218</ArticleId>
            <ArticleId IdType="pmc">PMC6096736</ArticleId>
            <ArticleId IdType="pubmed">29982279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, et al. . Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. (2019) 25:470–6. 10.1038/s41591-018-0339-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0339-5</ArticleId>
            <ArticleId IdType="pubmed">30742120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim IS, Gao Y, Welte T, Wang H, Liu J, Janghorban M. Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nat Cell Biol. (2019) 21:1113–26. 10.1038/s41556-019-0373-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-019-0373-7</ArticleId>
            <ArticleId IdType="pmc">PMC6726554</ArticleId>
            <ArticleId IdType="pubmed">31451770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, et al. . PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer. Int J Mol Sci. (2019) 20:1631. 10.3390/ijms20071631</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20071631</ArticleId>
            <ArticleId IdType="pmc">PMC6479779</ArticleId>
            <ArticleId IdType="pubmed">30986912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhuo M, Chen H, Zhang T, Yang X, Zhong J, Wang Y, et al. . The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients. Cancer Biomark. (2018) 22:467–76. 10.3233/CBM-171089</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/CBM-171089</ArticleId>
            <ArticleId IdType="pubmed">29758930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, et al. . Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. (2018) 6:141. 10.1186/s40425-018-0463-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0463-2</ArticleId>
            <ArticleId IdType="pmc">PMC6280368</ArticleId>
            <ArticleId IdType="pubmed">30514390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertelli G, Trovato R, Ugel S, Bria E, Milella M, Bronte V, et al. 
Characterization of myeloid-derived suppressor cells in a patient with lung adenocarcinoma undergoing durvalumab treatment: a case report. Clin Lung Cancer. (2019) 20:e514–6. 10.1016/j.cllc.2019.04.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cllc.2019.04.013</ArticleId>
            <ArticleId IdType="pubmed">31122866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. 
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. (2018) 24:749–57. 10.1038/s41591-018-0053-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0053-3</ArticleId>
            <ArticleId IdType="pmc">PMC6721896</ArticleId>
            <ArticleId IdType="pubmed">29867230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JW, Bellmunt J, Powles T, Loriot Y, Vogelzang NJ, Cruz Zambrano C, et al. 
Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: additional analysis from phase IA study. JCO. (2015) 33 (Suppl. 7):297. 10.1200/jco.2015.33.7_suppl.297</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2015.33.7_suppl.297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Cruz Zambrano C, et al. 
A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC). JCO. (2015) 33:4501
10.1200/jco.2015.33.15_suppl.4501</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2015.33.15_suppl.4501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo X, White W, Jin D.
Differential association of myeloid cell and IFN-γ associated proteins with clinical response to durvalumab treatment in urothelial bladder cancer. J Immunother Cancer. (2017) 5 (Suppl. 2):P32. Available online at: https://jitc.biomedcentral.com/articles/10.1186/s40425-017-0289-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0289-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao Y, Rabe C, Kowanetz M, Powles T, Vogelzang NJ, Petrylak DP, et al. 
Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer. J Immunother Cancer. (2014) 2(Suppl. 3):P131. 10.1186/2051-1426-2-S3-P131</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2051-1426-2-S3-P131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A, Kefford R, Marshall MA, Punt CJA, Haanen JB, Marmol M, et al. . Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. (2013) 31:616–22. 10.1200/JCO.2012.44.6112</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2012.44.6112</ArticleId>
            <ArticleId IdType="pmc">PMC4878048</ArticleId>
            <ArticleId IdType="pubmed">23295794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Retseck J, Nasr A, Lin Y, Lin H, Mendiratta P, Butterfield LH, et al. . Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. J Transl Med. (2018) 16:184. 10.1186/s12967-018-1563-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-018-1563-y</ArticleId>
            <ArticleId IdType="pmc">PMC6033230</ArticleId>
            <ArticleId IdType="pubmed">29973204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, et al. . Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. (2014) 63:247–57. 10.1007/s00262-013-1508-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-013-1508-5</ArticleId>
            <ArticleId IdType="pubmed">24357148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjoern J, Juul Nitschke N, Zeeberg Iversen T, Schmidt H, Fode K, Svane IM. Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology. (2016) 5:e1100788. 10.1080/2162402X.2015.1100788</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2015.1100788</ArticleId>
            <ArticleId IdType="pmc">PMC4839337</ArticleId>
            <ArticleId IdType="pubmed">27141381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Coaña YP, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nyström M, et al. . Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget. (2017) 8:21539–53. 10.18632/oncotarget.15368</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.15368</ArticleId>
            <ArticleId IdType="pmc">PMC5400604</ArticleId>
            <ArticleId IdType="pubmed">28423487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, et al. 
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res. (2016) 22:2908–18. 10.1158/1078-0432.CCR-15-2412</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-2412</ArticleId>
            <ArticleId IdType="pmc">PMC5770142</ArticleId>
            <ArticleId IdType="pubmed">26787752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, et al. . Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res. (2015) 21:5453–9. 10.1158/1078-0432.CCR-15-0676</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0676</ArticleId>
            <ArticleId IdType="pubmed">26289067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, et al. . Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J Clin Invest. (2018) 128:5505–16. 10.1172/JCI98060</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI98060</ArticleId>
            <ArticleId IdType="pmc">PMC6264733</ArticleId>
            <ArticleId IdType="pubmed">30260323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, et al. . Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer. (2014) 2:31. 10.1186/s40425-014-0031-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-014-0031-3</ArticleId>
            <ArticleId IdType="pmc">PMC4507359</ArticleId>
            <ArticleId IdType="pubmed">26196012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Damuzzo V, Solito S, Pinton L, Carrozzo E, Valpione S, Pigozzo J, et al. . Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. Oncoimmunology. (2016) 5:e1249559. 10.1080/2162402X.2016.1249559</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2016.1249559</ArticleId>
            <ArticleId IdType="pmc">PMC5215225</ArticleId>
            <ArticleId IdType="pubmed">28123888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, et al. . Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA. (2015) 112:6140–5. 10.1073/pnas.1417320112</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1417320112</ArticleId>
            <ArticleId IdType="pmc">PMC4434760</ArticleId>
            <ArticleId IdType="pubmed">25918390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, et al. . Clinical significance of circulating CD33+CD11b+HLA-DR–myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clin Cancer Res. (2016) 22:5661–72. 10.1158/1078-0432.CCR-15-3104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-3104</ArticleId>
            <ArticleId IdType="pubmed">27178742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, et al. . Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS ONE. (2014) 9:e87705. 10.1371/journal.pone.0087705</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0087705</ArticleId>
            <ArticleId IdType="pmc">PMC3912016</ArticleId>
            <ArticleId IdType="pubmed">24498358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pico de Coaña Y, Poschke I, Gentilcore G, Mao Y, Nyström M, Hansson J, et al. 
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their arginase1 production. Cancer Immunol Res. (2013) 1:158–162. 10.1158/2326-6066.CIR-13-0016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-13-0016</ArticleId>
            <ArticleId IdType="pubmed">24777678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, et al. . Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. (2018) 29:524. 10.1093/annonc/mdx059</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx059</ArticleId>
            <ArticleId IdType="pubmed">28379318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji R-R, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. . An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. (2012) 61:1019–31. 10.1007/s00262-011-1172-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-011-1172-6</ArticleId>
            <ArticleId IdType="pubmed">22146893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. . Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. (2015) 350:207–11. 10.1126/science.aad0095</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad0095</ArticleId>
            <ArticleId IdType="pmc">PMC5054517</ArticleId>
            <ArticleId IdType="pubmed">26359337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harder N, Schönmeyer R, Nekolla K, Meier A, Brieu N, Vanegas C, et al. . Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. Sci Rep. (2019) 9:7449. 10.1038/s41598-019-43525-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-43525-8</ArticleId>
            <ArticleId IdType="pmc">PMC6520405</ArticleId>
            <ArticleId IdType="pubmed">31092853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, et al. . PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. Oncoimmunology. (2018) 7:e1405206. 10.1080/2162402X.2017.1405206</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2017.1405206</ArticleId>
            <ArticleId IdType="pmc">PMC6279420</ArticleId>
            <ArticleId IdType="pubmed">30524879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capone M, Madonna G, Ascierto P, Danaher P, Ong S, Warren S, et al. 
Abstract 558: prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma. Cancer Res. (2018) 78:558
10.1158/1538-7445.AM2018-558</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2018-558</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, et al. . Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell. (2018) 33:649–63.e4. 10.1016/j.ccell.2018.02.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.02.010</ArticleId>
            <ArticleId IdType="pmc">PMC5904288</ArticleId>
            <ArticleId IdType="pubmed">29576375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, et al. . In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy. Sci Transl Med. (2017) 9:eaal3604. 10.1126/scitranslmed.aal3604</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aal3604</ArticleId>
            <ArticleId IdType="pmc">PMC5734617</ArticleId>
            <ArticleId IdType="pubmed">28490665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W, et al. . The binding of an anti-PD-1 antibody to FcγR? has a profound impact on its biological functions. Cancer Immunol Immunother. (2018) 67:1079–90. 10.1007/s00262-018-2160-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-018-2160-x</ArticleId>
            <ArticleId IdType="pmc">PMC6006217</ArticleId>
            <ArticleId IdType="pubmed">29687231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rashidian M, LaFleur MW, Verschoor VL, Dongre A, Zhang Y, Nguyen TH, et al. . Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Proc Natl Acad Sci USA. (2019) 116:16971–80. 10.1073/pnas.1905005116</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1905005116</ArticleId>
            <ArticleId IdType="pmc">PMC6708368</ArticleId>
            <ArticleId IdType="pubmed">31375632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, et al. 
High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell. (2018) 175:1014–30.e19. 10.1016/j.cell.2018.09.030</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.09.030</ArticleId>
            <ArticleId IdType="pmc">PMC6501221</ArticleId>
            <ArticleId IdType="pubmed">30343900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med. (2018) 7:2654–64. 10.1002/cam4.1518</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.1518</ArticleId>
            <ArticleId IdType="pmc">PMC6010882</ArticleId>
            <ArticleId IdType="pubmed">29733528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. . PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. (2017) 545:495–9. 10.1038/nature22396</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature22396</ArticleId>
            <ArticleId IdType="pmc">PMC5931375</ArticleId>
            <ArticleId IdType="pubmed">28514441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Cao M-F, Xiao J-F, Ma Q-H, Zhang H, Cai R-L, et al. . Stromal PD-1+ tumor-associated macrophages predict poor prognosis in lung adenocarcinoma. Hum Pathol. (2020) 97:68–79. 10.1016/j.humpath.2019.12.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humpath.2019.12.007</ArticleId>
            <ArticleId IdType="pubmed">31926212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW. Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res. (2018) 6:1260–73. 10.1158/2326-6066.CIR-17-0537</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-17-0537</ArticleId>
            <ArticleId IdType="pubmed">30012633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?
Am Soc Clin Oncol Educ Book. (2019) 39:147–64. 10.1200/EDBK_240837</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/EDBK_240837</ArticleId>
            <ArticleId IdType="pubmed">31099674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wainberg ZA, Piha-Paul SA, Luke J, Kim EJ, Thompson JA, Johnson JM, et al. 
First-in-human phase 1 dose escalation and expansion of a novel combination, anti-CSF-1 receptor (cabiralizumab) plus anti-PD-1 (nivolumab). In: Patients With Advanced Solid Tumors.
10.13140/rg.2.2.28962.53443</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.13140/rg.2.2.28962.53443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carleton M, Powers J, Phillips P, Beg MS, Lee JJ, Rahma OE, et al. 
Wainberg Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications. J Clin Oncol. (2018) 36(15_suppl):3020. 10.1200/JCO.2018.36.15_suppl.3020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.3020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wainberg ZA, Eisenberg PD, Sachdev JC, Weise AM, Kaufman DR, Hutchinson M, et al. 
Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. JCO. (2016) 34 (Suppl. 4):TPS465. 10.1200/jco.2016.34.4_suppl.tps465</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2016.34.4_suppl.tps465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harb WA, Johnson ML, Goldman JW, Weise AM, Call JA, Dudek AZ, et al. 
A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors. JCO. (2017) 35 (Suppl. 15):TPS3110. 10.1200/JCO.2017.35.15_suppl.TPS3110</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.35.15_suppl.TPS3110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassier PA, Garin G, Eberst L, Delord J-P, Chabaud S, Terret C, et al. 
MEDIPLEX: a phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). JCO. (2019) 37:2579–9. 10.1200/JCO.2019.37.15_suppl.2579</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.2579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, et al. . Targeting CD73 in the tumor microenvironment with MEDI9447. OncoImmunology. (2016) 5:e1208875. 10.1080/2162402X.2016.1208875</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2016.1208875</ArticleId>
            <ArticleId IdType="pmc">PMC5007986</ArticleId>
            <ArticleId IdType="pubmed">27622077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiappori A, Williams CC, Creelan BC, Tanvetyanon T, Gray JE, Haura EB, et al. 
Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC. JCO. (2018) 36:9089
10.1200/JCO.2018.36.15_suppl.9089</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.9089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fong L, Forde PM, Powderly JD, Goldman JW, Nemunaitis JJ, Luke JJ, et al. 
Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients. JCO. (2017) 35:3004
10.1200/JCO.2017.35.15_suppl.3004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.35.15_suppl.3004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willingham S, Hotson AN, Laport G, Kwei L, Fong L, Sznol M, et al. 
Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444. Ann Oncol. (2018) 29:viii403–4. 10.1093/annonc/mdy288.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy288.010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bendell J, Bauer T, Patel M, Falchook G, Karlix JL, Lim E, et al. 
Evidence of immune activation in the first-in-human phase ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors. Cancer Res. (2019) 79
10.1158/1538-7445.AM2019-CT026</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2019-CT026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lesinski GB, Fisher TL, Evans EE, Leonard JE, Pastore DR, Mallow C, et al. 
Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors. Cancer Res. (2019) 79:CT016
10.1158/1538-7445.AM2019-CT016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2019-CT016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lowe MC, Lesinski GB, Delman KA, Yushak ML, Evans EE, Fisher TL, et al. 
Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma. JCO. (2019) 37:TPS9603
10.1200/JCO.2019.37.15_suppl.TPS9603</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.TPS9603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, et al. 
Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. JCO. (2019) 37:2601–2601. 10.1200/JCO.2019.37.15_suppl.2601</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.2601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, et al. . Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase i results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). JCO. (2018) 36:3223–30. 10.1200/JCO.2018.78.9602</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.78.9602</ArticleId>
            <ArticleId IdType="pmc">PMC6225502</ArticleId>
            <ArticleId IdType="pubmed">30265610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. . Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. (2019) 20:1083–97. 10.1016/S1470-2045(19)30274-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(19)30274-8</ArticleId>
            <ArticleId IdType="pubmed">31221619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powles T, Bellmunt J, Petrylak DP, Fong L, Nishiyama H, Sternberg CN, et al. 
Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303. JCO. (2018) 36:TPS4586
10.1200/JCO.2018.36.15_suppl.TPS4586</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.TPS4586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen EEW, Rischin D, Pfister DG, Vermorken JB, Zhao Y, Gowda H, et al. 
A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669. JCO. (2018) 36 (Suppl. 15):TPS6090. 10.1200/JCO.2018.36.15_suppl.TPS6090</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.TPS6090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Awad MM, Munteanu M, Zhao Y, Xu L, Samkari A, Paz-Ares LG.
ECHO-305/KEYNOTE-654: a phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non–small cell lung cancer (mNSCLC) with high PD-L1 levels. JCO. (2018) 36 (Suppl. 15):TPS9109. 10.1200/JCO.2018.36.15_suppl.TPS9109</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.TPS9109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui R, Munteanu M, Zhao Y, Luo Y, Samkari A, Garassino MC. ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non–small cell lung cancer (mNSCLC). JCO. (2018) 36 (Suppl. 15):TPS9104. 10.1200/JCO.2018.36.15_suppl.TPS9104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.TPS9104</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balar AV, Plimack ER, Grivas P, Necchi A, De Santis M, Pang L, et al. 
Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307. JCO. (2018) 36 (Suppl. 15):TPS4587. 10.1200/JCO.2018.36.15_suppl.TPS4587</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.TPS4587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naing A, Powderly JD, Falchook G, Creelan B, Nemunaitis J, Lutzky J, et al. 
Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study. Cancer Res. (2018) 78:CT177
10.1158/1538-7445.AM2018-CT177</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2018-CT177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, et al. 
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer. (2019) 7:1–13. 10.1186/s40425-019-0562-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0562-8</ArticleId>
            <ArticleId IdType="pmc">PMC6425606</ArticleId>
            <ArticleId IdType="pubmed">30894212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan RJ, Hong DS, Tolcher AW, Patnaik A, Shapiro G, Chmielowski B, et al. 
Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. JCO. (2018) 36:3013
10.1200/JCO.2018.36.15_suppl.3013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.3013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Hara MH, O'Reilly EM, Rosemarie M, Varadhachary G, Wainberg ZA, Ko A, et al. 
Abstract CT004: a phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. Cancer Res. (2019) 79:CT004
10.1158/1538-7445.AM2019-CT004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2019-CT004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrington KJ, Brody J, Ingham M, Strauss J, Cemerski S, Wang M, et al. 
Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. Ann Oncol. (2018) 29:viii712
10.1093/annonc/mdy424.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy424.015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meric-Bernstam F, Sandhu SK, Hamid O, Spreafico A, Kasper S, Dummer R, et al. 
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. JCO. (2019) 37:2507–7. 10.1200/JCO.2019.37.15_suppl.2507</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.2507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, et al. . Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. (2018) 63:282–91. 10.1016/j.intimp.2018.08.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2018.08.007</ArticleId>
            <ArticleId IdType="pmc">PMC6134177</ArticleId>
            <ArticleId IdType="pubmed">30121453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chawla SP, Sankhala KK, Ravicz J, Kang G, Liu S, Stumpf N, et al. 
Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma. JCO. (2018) 36 (Suppl. 15):e23568. 10.1200/JCO.2018.36.15_suppl.e23568</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.e23568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon EM, Chua-Alcala VS, Kim K, Tseng WW, Quon DM, Chawla SP.
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab, and nivolumab as first-line treatment of advanced soft tissue sarcoma (STS). JCO. (2018) 36 (Suppl. 5):TPS46. 10.1200/JCO.2018.36.5_suppl.TPS46</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.5_suppl.TPS46</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. . Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. (2018) 19:405–15. 10.1016/S1470-2045(18)30081-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30081-0</ArticleId>
            <ArticleId IdType="pmc">PMC6860026</ArticleId>
            <ArticleId IdType="pubmed">29439857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. . Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. (2019) 380:1116–27. 10.1056/NEJMoa1816714</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1816714</ArticleId>
            <ArticleId IdType="pubmed">30779529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. . Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. (2019) 380:1103–15. 10.1056/NEJMoa1816047</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1816047</ArticleId>
            <ArticleId IdType="pmc">PMC6716603</ArticleId>
            <ArticleId IdType="pubmed">30779531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahluwalia M, Peereboom D, Schilero C, Forst D, Wong E, Wen P, et al. 
RBTT-01. randomized phase 2 open label study of nivolumab plus standard dose bevacizumab versus nivolumab plus low dose bevacizumab in recurrent glioblastoma. Neuro Oncol. (2018) 20:vi234
10.1093/neuonc/noy148.971</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noy148.971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, et al. . Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. (2016) 7:1–8. 10.1038/ncomms12624</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms12624</ArticleId>
            <ArticleId IdType="pmc">PMC5013615</ArticleId>
            <ArticleId IdType="pubmed">27571927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stein S, Pishvaian MJ, Lee MS, Lee K-H, Hernandez S, Kwan A, et al. 
Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). JCO. (2018) 36 (Suppl. 15):4074. 10.1200/JCO.2018.36.15_suppl.4074</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.4074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. . Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. (2018) 378:2288–301. 10.1056/NEJMoa1716948</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1716948</ArticleId>
            <ArticleId IdType="pubmed">29863955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, et al. . Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. (2019) 7:387–401. 10.1016/S2213-2600(19)30084-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(19)30084-0</ArticleId>
            <ArticleId IdType="pubmed">30922878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. . Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. (2019) 393:2404–15. 10.1016/S0140-6736(19)30723-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(19)30723-8</ArticleId>
            <ArticleId IdType="pubmed">31079938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. 
Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. (2014) 2:632–42. 10.1158/2326-6066.CIR-14-0053</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0053</ArticleId>
            <ArticleId IdType="pmc">PMC4306338</ArticleId>
            <ArticleId IdType="pubmed">24838938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J, et al. . Angiopoietin-2 as a biomarker and target for immune checkpoint therapy. Cancer Immunol Res. (2017) 5:17–28. 10.1158/2326-6066.CIR-16-0206</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0206</ArticleId>
            <ArticleId IdType="pmc">PMC5215959</ArticleId>
            <ArticleId IdType="pubmed">28003187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, Li J, Connolly EM, Liao X, Ouyang J, Giobbie-Hurder A, et al. . Combined anti-VEGF and anti–CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes. Cancer Immunol Res. (2017) 5:446–54. 10.1158/2326-6066.CIR-16-0385</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0385</ArticleId>
            <ArticleId IdType="pmc">PMC5509159</ArticleId>
            <ArticleId IdType="pubmed">28473314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, Giobbie-Hurder A, Liao X, Lawrence D, McDermott D, Zhou J, et al. . VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma. Cancer Immunol Res. (2016) 4:858–68. 10.1158/2326-6066.CIR-16-0084</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0084</ArticleId>
            <ArticleId IdType="pmc">PMC5050160</ArticleId>
            <ArticleId IdType="pubmed">27549123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, Giobbie-Hurder A, Connolly EM, Li J, Liao X, Severgnini M, et al. . Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. OncoImmunology. (2018) 7:e1440930. 10.1080/2162402X.2018.1440930</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1440930</ArticleId>
            <ArticleId IdType="pmc">PMC5993498</ArticleId>
            <ArticleId IdType="pubmed">29900046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. (2014) 6:a021857. 10.1101/cshperspect.a021857</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a021857</ArticleId>
            <ArticleId IdType="pmc">PMC4031967</ArticleId>
            <ArticleId IdType="pubmed">24890514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. . CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. (2014) 74:5057–69. 10.1158/0008-5472.CAN-13-3723</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-3723</ArticleId>
            <ArticleId IdType="pmc">PMC4182950</ArticleId>
            <ArticleId IdType="pubmed">25082815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, et al. . Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. (2014) 74:153–61. 10.1158/0008-5472.CAN-13-1816</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-1816</ArticleId>
            <ArticleId IdType="pmc">PMC3947337</ArticleId>
            <ArticleId IdType="pubmed">24247719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cannarile MA, Weisser M, Jacob W, Jegg A-M, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. (2017) 5:53. 10.1186/s40425-017-0257-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0257-y</ArticleId>
            <ArticleId IdType="pmc">PMC5514481</ArticleId>
            <ArticleId IdType="pubmed">28716061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. . Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. (2014) 25:846–59. 10.1016/j.ccr.2014.05.016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2014.05.016</ArticleId>
            <ArticleId IdType="pubmed">24898549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anthony SP, Puzanov I, Lin PS, Nolop KB, West B, Von Hoff DD.
Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and kit. JCO. (2011) 29:3093
10.1200/jco.2011.29.15_suppl.3093</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2011.29.15_suppl.3093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang-Gillam A, O'Reilly EM, Bendell J, Wainberg ZA, Borazanci E, Bahary N, et al. 
A randomized phase 2 study of cabiralizumab + nivolumab ± chemotherapy in advanced pancreatic ductal adenocarcinoma. J Clin Oncol. (2019) 37 (Suppl 4). 10.1200/JCO.2019.37.4_suppl.TPS465</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.4_suppl.TPS465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. (2017) 276:121–44. 10.1111/imr.12528</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12528</ArticleId>
            <ArticleId IdType="pmc">PMC5338647</ArticleId>
            <ArticleId IdType="pubmed">28258700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol. (2016) 29:7–16. 10.1016/j.coph.2016.04.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coph.2016.04.001</ArticleId>
            <ArticleId IdType="pubmed">27209048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linden J, Cekic C. Regulation of lymphocyte function by adenosine. Arterioscler Thromb Vasc Biol. (2012) 32:2097–103. 10.1161/ATVBAHA.111.226837</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/ATVBAHA.111.226837</ArticleId>
            <ArticleId IdType="pmc">PMC4476649</ArticleId>
            <ArticleId IdType="pubmed">22772752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hotson D, Powderly J, Emens L, Forde P, Hellmann M, Markman B, et al. 
Clinical Activity of Adenosine A2A Receptor (A2aR) Inhibitor CPI-444 is Associated With Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation. Available online at: https://www.corvuspharma.com/file.cfm/23/docs/SITC_2017_Slides.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Ch'ng ES, Kumanogoh A. Roles of sema4D and plexin-B1 in tumor progression. Mol Cancer. (2010) 9:251. 10.1186/1476-4598-9-251</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-9-251</ArticleId>
            <ArticleId IdType="pmc">PMC2955613</ArticleId>
            <ArticleId IdType="pubmed">20858260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans EE, Paris M, Smith ES, Zauderer M. Immunomodulation of the tumor microenvironment by neutralization of semaphorin 4D. Oncoimmunology. (2015) 4:e1054599
10.1080/2162402X.2015.1054599</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2015.1054599</ArticleId>
            <ArticleId IdType="pmc">PMC4635900</ArticleId>
            <ArticleId IdType="pubmed">26587332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans EE, Jonason AS, Bussler H, Torno S, Veeraraghavan J, Reilly C, et al. . Antibody blockade of semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies. Cancer Immunol Res. (2015) 3:689–701. 10.1158/2326-6066.CIR-14-0171</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0171</ArticleId>
            <ArticleId IdType="pubmed">25614511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. (1999) 189:1363–72. 10.1084/jem.189.9.1363</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.189.9.1363</ArticleId>
            <ArticleId IdType="pmc">PMC2193062</ArticleId>
            <ArticleId IdType="pubmed">10224276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma MD, Baban B, Chandler P, Hou D-Y, Singh N, Yagita H, et al. . Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. (2007) 117:2570–82. 10.1172/JCI31911</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI31911</ArticleId>
            <ArticleId IdType="pmc">PMC1940240</ArticleId>
            <ArticleId IdType="pubmed">17710230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al. . Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. (2004) 114:280–90. 10.1172/JCI21583</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI21583</ArticleId>
            <ArticleId IdType="pmc">PMC449750</ArticleId>
            <ArticleId IdType="pubmed">15254595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. . Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. (2003) 9:1269–74. 10.1038/nm934</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm934</ArticleId>
            <ArticleId IdType="pubmed">14502282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J. (1991) 5:2516–22. 10.1096/fasebj.5.11.1907934</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fasebj.5.11.1907934</ArticleId>
            <ArticleId IdType="pubmed">1907934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. . A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. (2011) 9:1–16. 10.1186/1479-5876-9-204</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-9-204</ArticleId>
            <ArticleId IdType="pmc">PMC3239318</ArticleId>
            <ArticleId IdType="pubmed">22123319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. (2013) 210:1389–402. 10.1084/jem.20130066</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20130066</ArticleId>
            <ArticleId IdType="pmc">PMC3698523</ArticleId>
            <ArticleId IdType="pubmed">23752227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, et al. . Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. OncoImmunology. (2015) 4:e982382. 10.4161/2162402X.2014.982382</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/2162402X.2014.982382</ArticleId>
            <ArticleId IdType="pmc">PMC4404886</ArticleId>
            <ArticleId IdType="pubmed">25949897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. . Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. (2010) 115:3520–30. 10.1182/blood-2009-09-246124</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2009-09-246124</ArticleId>
            <ArticleId IdType="pubmed">20197554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, et al. . The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget. (2016) 7:37762–72. 10.18632/oncotarget.9326</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.9326</ArticleId>
            <ArticleId IdType="pmc">PMC5122347</ArticleId>
            <ArticleId IdType="pubmed">27192116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van den Eynde BJ, van Baren N, Baurain J-F.
Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma?
Ann Rev Cancer Biol. (2020) 4:241–56. 10.1146/annurev-cancerbio-030419-033635</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-cancerbio-030419-033635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gyori D, Chessa T, Hawkins PT, Stephens LR. Class (I) phosphoinositide 3-kinases in the tumor microenvironment. Cancers (Basel). (2017) 9:24. 10.3390/cancers9030024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers9030024</ArticleId>
            <ArticleId IdType="pmc">PMC5366819</ArticleId>
            <ArticleId IdType="pubmed">28273837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaneda MM, Messer KS, Ralainirina N, Li H, Leem C, Gorjestani S, et al. . PI3Kγ is a molecular switch that controls immune suppression. Nature. (2016) 539:437–42. 10.1038/nature19834</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature19834</ArticleId>
            <ArticleId IdType="pmc">PMC5479689</ArticleId>
            <ArticleId IdType="pubmed">27642729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henau OD, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. . Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. (2016) 539:443–7. 10.1038/nature20554</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature20554</ArticleId>
            <ArticleId IdType="pmc">PMC5634331</ArticleId>
            <ArticleId IdType="pubmed">27828943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Ann Rev Immunol. (2004) 22:307–28. 10.1146/annurev.immunol.22.012703.104533</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.22.012703.104533</ArticleId>
            <ArticleId IdType="pubmed">15032580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AHR, Ugel S, et al. 
T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell. (2016) 30:377–90. 10.1016/j.ccell.2016.08.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2016.08.004</ArticleId>
            <ArticleId IdType="pmc">PMC5023283</ArticleId>
            <ArticleId IdType="pubmed">27622331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, et al. 
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget. (2016) 7:18508–20. 10.18632/oncotarget.7610</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.7610</ArticleId>
            <ArticleId IdType="pmc">PMC4951305</ArticleId>
            <ArticleId IdType="pubmed">26918344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer ARL, Bajor DL, et al. . Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. (2015) 3:399–411. 10.1158/2326-6066.CIR-14-0215</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0215</ArticleId>
            <ArticleId IdType="pmc">PMC4390506</ArticleId>
            <ArticleId IdType="pubmed">25678581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zippelius A, Schreiner J, Herzig P, Müller P. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. (2015) 3:236–44. 10.1158/2326-6066.CIR-14-0226</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0226</ArticleId>
            <ArticleId IdType="pubmed">25623164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macherla S, Laks S, Naqash AR, Bulumulle A, Zervos E, Muzaffar M. Emerging role of immune checkpoint blockade in pancreatic cancer. Int J Mol Sci. (2018) 19:3505. 10.3390/ijms19113505</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19113505</ArticleId>
            <ArticleId IdType="pmc">PMC6274962</ArticleId>
            <ArticleId IdType="pubmed">30405053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuertes MB, Kacha AK, Kline J, Woo S-R, Kranz DM, Murphy KM, et al. . Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med. (2011) 208:2005–16. 10.1084/jem.20101159</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20101159</ArticleId>
            <ArticleId IdType="pmc">PMC3182064</ArticleId>
            <ArticleId IdType="pubmed">21930765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. . Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. (2011) 208:1989–2003. 10.1084/jem.20101158</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20101158</ArticleId>
            <ArticleId IdType="pmc">PMC3182061</ArticleId>
            <ArticleId IdType="pubmed">21930769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo S-R, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MYK, et al. . STING-Dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. (2014) 41:830–42. 10.1016/j.immuni.2014.10.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.10.017</ArticleId>
            <ArticleId IdType="pmc">PMC4384884</ArticleId>
            <ArticleId IdType="pubmed">25517615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, Fitzgerald KA, et al. . 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem. (2012) 287:39776–88. 10.1074/jbc.M112.382986</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M112.382986</ArticleId>
            <ArticleId IdType="pmc">PMC3501038</ArticleId>
            <ArticleId IdType="pubmed">23027866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conlon J, Burdette DL, Sharma S, Bhat N, Thompson M, Jiang Z, et al. . Mouse, but not human sting, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol. (2013) 190:5216–25. 10.4049/jimmunol.1300097</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1300097</ArticleId>
            <ArticleId IdType="pmc">PMC3647383</ArticleId>
            <ArticleId IdType="pubmed">23585680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agrawal S, Kandimalla ER.
Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors. Immun Oncol Technol. (2019) 3:15–23. 10.1016/j.iotech.2019.10.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.iotech.2019.10.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubensky TW.
STING at a Crossroads: Untapped Potential for Innate Immunity. Available online at: https://www.tempesttx.com/file.cfm/24/docs/2019%20SITC%20Oral%20Presentation%20_STING%20at%20a%20Crossroads%20-%20Untapped%20Potential%20for%20Innate%20Immunity.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang S-Y, et al. . Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. (2018) 564:439–43. 10.1038/s41586-018-0705-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-018-0705-y</ArticleId>
            <ArticleId IdType="pubmed">30405246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ching L-M, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. (2002) 86:1937–42. 10.1038/sj.bjc.6600368</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6600368</ArticleId>
            <ArticleId IdType="pmc">PMC2375421</ArticleId>
            <ArticleId IdType="pubmed">12085190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moilanen E, Thomsen LL, Miles DW, Happerfield DW, Knowles RG, Moncada S. Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. (1998) 77:426–33. 10.1038/bjc.1998.68</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.1998.68</ArticleId>
            <ArticleId IdType="pmc">PMC2151290</ArticleId>
            <ArticleId IdType="pubmed">9472639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun J, Wang L-CS, Fridlender ZG, Kapoor V, Cheng G, Ching L-M, et al. . Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation. Biochem Pharmacol. (2011) 82:1175–85. 10.1016/j.bcp.2011.07.086</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2011.07.086</ArticleId>
            <ArticleId IdType="pmc">PMC3191304</ArticleId>
            <ArticleId IdType="pubmed">21819972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Downey CM, Aghaei M, Schwendener RA, Jirik FR. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2′3′-cGAMP, induces M2 macrophage repolarization. PLoS ONE. (2014) 9:e99988. 10.1371/journal.pone.0099988</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0099988</ArticleId>
            <ArticleId IdType="pmc">PMC4062468</ArticleId>
            <ArticleId IdType="pubmed">24940883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. . Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. (2015) 11:1018–30. 10.1016/j.celrep.2015.04.031</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2015.04.031</ArticleId>
            <ArticleId IdType="pmc">PMC4440852</ArticleId>
            <ArticleId IdType="pubmed">25959818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss JM, Guérin MV, Regnier F, Renault G, Galy-Fauroux I, Vimeux L, et al. . The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression. OncoImmunology. (2017) 6:e1346765. 10.1080/2162402X.2017.1346765</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2017.1346765</ArticleId>
            <ArticleId IdType="pmc">PMC5665074</ArticleId>
            <ArticleId IdType="pubmed">29123960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lara PN, Douillard J-Y, Nakagawa K, von Pawel J, McKeage MJ, Albert I, et al. 
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non–small-cell lung cancer. JCO. (2011) 29:2965–71. 10.1200/JCO.2011.35.0660</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2011.35.0660</ArticleId>
            <ArticleId IdType="pubmed">21709202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meric-Bernstam F, Werner TL, Hodi FS, Messersmith W, Lewis N, Talluto C, et al. 
Phase I dose-finding study of MIW815 (ADU-S100), an intratumoral STING agonist. In: Patients With Advanced Solid Tumors or Lymphomas. Available online at: https://www.aduro.com/file.cfm/13/docs/SITC18_MIW815X2101_SITC%20Poster(e_version)_08Nov2018.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. (2007) 67:11021–8. 10.1158/0008-5472.CAN-07-2593</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2593</ArticleId>
            <ArticleId IdType="pubmed">18006848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. . Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. (1988) 72:567–72. 10.1182/blood.V72.2.567.bloodjournal722567</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V72.2.567.bloodjournal722567</ArticleId>
            <ArticleId IdType="pubmed">3165295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iclozan C, Antonia S, Chiappori A, Chen D-T, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. (2013) 62:909–18. 10.1007/s00262-013-1396-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-013-1396-8</ArticleId>
            <ArticleId IdType="pmc">PMC3662237</ArticleId>
            <ArticleId IdType="pubmed">23589106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grosso F, Jones RL, Demetri GD, Judson IR, Blay J-Y, Le Cesne A, et al. . Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. (2007) 8:595–602. 10.1016/S1470-2045(07)70175-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(07)70175-4</ArticleId>
            <ArticleId IdType="pubmed">17586092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. . Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. JCO. (2010) 28:3107–14. 10.1200/JCO.2009.25.4037</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.25.4037</ArticleId>
            <ArticleId IdType="pubmed">20516432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, et al. . Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. (2013) 23:249–62. 10.1016/j.ccr.2013.01.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2013.01.008</ArticleId>
            <ArticleId IdType="pubmed">23410977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Z, Wang H, Meng F, Li J, Zhang S. Combined trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. J Transl Med. (2015) 13:247. 10.1186/s12967-015-0613-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-015-0613-y</ArticleId>
            <ArticleId IdType="pmc">PMC4517526</ArticleId>
            <ArticleId IdType="pubmed">26219551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. . Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. (1996) 2:1096–103. 10.1038/nm1096-1096</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1096-1096</ArticleId>
            <ArticleId IdType="pubmed">8837607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, et al. . The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother. (2008) 57:1115–24. 10.1007/s00262-007-0441-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-007-0441-x</ArticleId>
            <ArticleId IdType="pmc">PMC4110970</ArticleId>
            <ArticleId IdType="pubmed">18193223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. (2001) 23:263–72. 10.1385/IR:23:2-3:263</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1385/IR:23:2-3:263</ArticleId>
            <ArticleId IdType="pubmed">11444391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. (2009) 9:162–74. 10.1038/nri2506</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2506</ArticleId>
            <ArticleId IdType="pmc">PMC2828349</ArticleId>
            <ArticleId IdType="pubmed">19197294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. (2010) 70:6171–80. 10.1158/0008-5472.CAN-10-0153</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-10-0153</ArticleId>
            <ArticleId IdType="pmc">PMC2912959</ArticleId>
            <ArticleId IdType="pubmed">20631075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. (2019) 18:60. 10.1186/s12943-019-0974-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-019-0974-6</ArticleId>
            <ArticleId IdType="pmc">PMC6441150</ArticleId>
            <ArticleId IdType="pubmed">30925919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forget MA, Voorhees JL, Cole SL, Dakhlallah D, Patterson IL, Gross AC, et al. 
Macrophage colony-stimulating factor augments tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. PLoS ONE. (2014) 9:e98623
10.1371/journal.pone.0098623</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0098623</ArticleId>
            <ArticleId IdType="pmc">PMC4043882</ArticleId>
            <ArticleId IdType="pubmed">24892425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol. (2007) 178:7405–11. 10.4049/jimmunol.178.11.7405</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.178.11.7405</ArticleId>
            <ArticleId IdType="pubmed">17513791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, et al. . Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. (2007) 109:5276–85. 10.1182/blood-2006-10-053504</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2006-10-053504</ArticleId>
            <ArticleId IdType="pubmed">17327411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune Suppression. Clin Cancer Res. (2019) 25:5449–57. 10.1158/1078-0432.CCR-18-1543</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1543</ArticleId>
            <ArticleId IdType="pubmed">30944124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen H, Liu Q, Li M, Yang P. The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis. Clin Invest Med. (2017) 40:E40–8. 10.25011/cim.v40i2.28194</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.25011/cim.v40i2.28194</ArticleId>
            <ArticleId IdType="pubmed">28447576</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
